News 2016-04-29
Vice Governor of Zhejiang Province Visits Porton Shangyu Site.
The vice governor of Zhejiang Province, Xiong Jianping, accompanied by other government officials visits Porton Shangyu Site on April 28th, 2016.
The president, Andrew Xu, give a presentation on Porton’s general situation, EHS conception, development planning, R&D investment and high-level Hardware facilities investment.
The vice governor and officials visit workshop, wastewater treatment facility and RTO equipment, give fully affirmation and admiration to the implement of international standard production facility design, investment and management. On the environmental protection aspect, source control, fully enclosed vertical flow workshop design, automation control and etc. are highly accepted by the governor.
The vice governor show to the entourage after on-the-spot investigation at Porton Shangyu Site, if other company operated according to Porton’s conception and management style, he is confidence on garden’s tail gas treatment and control. He also mentioned that the company could be better if they are willing to input, choose better equipment and excellent management.
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
